NASDAQ: URGN - UroGen Pharma Ltd.

Yield per half year: +25.1%
Sector: Healthcare

Share chart UroGen Pharma Ltd.


About

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer.

More details
It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for NMIBC. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

Main settings

Выручка 1.8E-5
EBITDA -0.1082
P/S 36358.66
P/BV 3.63
EV/EBITDA -5.62
Цена ао 15.17
ISIN IL0011407140
Число акций ао 0.02883 млрд
Сайт https://www.urogen.com
Change price per day: 0% (15.1)
Change price per week: +14.31% (13.21)
Change price per month: +5.37% (14.33)
Change price per 3 month: +3.5% (14.59)
Change price per half year: +25.1% (12.07)
Change price per year: +56.8% (9.63)
Change price per year to date: +4.14% (14.5)


All parameters ⇨

Grade

Underestimation

Title Value Grade
P/S 36358.66 3
P/BV 3.63 0
P/E 0 0
EV/EBITDA -5.62 0
Total:

Efficiency

Title Value Grade
ROA, % -65.01 0
ROE, % 132.82 10
Total:

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total:

Debt

Title Value Grade
Debt/EBITDA -1.5705 10
Total:

Growth impulse

Title Value Grade
Profit growth, % -7.51 0
Share price growth, % 0 0
Dividend growth, % 0 0
Total:

Main owners

Institutions Volume Share, %
Great Point Partners LLC 2620545 8.49
Menora Mivtachim Holdings Ltd. 2303031 7.46
RA Capital Management, L.P. 1483697 4.81
Blackrock Inc. 1197647 3.88
Credit Suisse Ag/ 1060000 3.43
Harel Insurance Investments & Financial Services Ltd. 870194 2.82
RTW Investments LP 857464 2.78
Migdal Insurance & Financial Holdings Ltd. 648302 2.1
SILVERARC CAPITAL MANAGEMENT, LLC 508883 1.65
Wildcat Capital Management, LLC 495606 1.61

Similar companies



Company management

Head Job title Payment Year of birth
Ms. Elizabeth A. Barrett President, CEO & Director 1.12M 1962 (62 years)
Mr. Dong Kim Chief Financial Officer 546.68k 1977 (47 years)
Mr. Jason Drew Smith General Counsel, Chief Compliance Officer & Corporate Secretary 717.58k 1972 (52 years)
Vincent I. Perrone Senior Director of Investor Relations N/A
Mr. Bryon Wornson Executive Vice President of Talent, Advocacy & Communications N/A
Dr. Sari Prutchi-Sagiv Ph.D. Marketing Director N/A
Dr. Marina Konorty Executive Vice President of Research & Development and Technical Operations N/A
Dr. Mark P. Schoenberg M.D. Chief Medical Officer 579.5k 1958 (66 years)
Mr. Jeffrey Bova M.B.A. Chief Commercial Officer N/A
Mr. James Ottinger R.ph. Executive Vice President of Regulatory Affairs & Quality N/A

About company

Address: United States, Princeton. NJ, 400 Alexander Park - open in Google maps, open in Yandex maps
Website: https://www.urogen.com
Phone: +tel:6467689780